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ABSTRACT
Objective: To determine whether raloxifene, a selective estrogen receptor modulator, improves
cognitive function compared with placebo in women with Alzheimer disease (AD) and to provide
an estimate of cognitive effect.
Methods: This pilot study was conducted as a randomized, double-blind, placebo-controlled trial,
with a planned treatment of 12 months. Women with late-onset AD of mild to moderate severity
were randomly allocated to high-dose (120 mg) oral raloxifene or identical placebo provided once
daily. The primary outcome compared between treatment groups at 12 months was change in the
Alzheimer’s Disease Assessment Scale, cognitive subscale (ADAS-cog).
Results: Forty-two women randomized to raloxifene or placebo were included in intent-to-treat
analyses (mean age 76 years, range 68–84), and 39 women contributed 12-month outcomes.
ADAS-cog change scores at 12 months did not differ significantly between treatment groups
(standardized difference 0.03, 95% confidence interval 20.39 to 0.44, 2-tailed p 5 0.89).
Raloxifene and placebo groups did not differ significantly on secondary analyses of dementia
rating, activities of daily living, behavior, or a global cognition composite score. Caregiver burden
and caregiver distress were similar in both groups.
Conclusions: Results on the primary outcome showed no cognitive benefits in the raloxifene-
treated group.
Classification of evidence: This study provides Class I evidence that for women with AD, raloxifene
does not have a significant cognitive effect. The study lacked the precision to exclude a small
effect. Neurology® 2015;85:1937–1944
GLOSSARY
AD5 Alzheimer disease; ADAS-cog5 Alzheimer’s Disease Assessment Scale, cognitive subscale; CI5 confidence interval;
SERM 5 selective estrogen receptor modulator.
The burden of Alzheimer disease (AD) falls heavily on women. By virtue of greater longevity,
more women than men survive to an older age when risk is greater. AD pathology is more likely
to be expressed as dementia in women than men,1 and cognitive symptoms appear to be more
severe.2 Estrogens have attracted interest as potential treatment for women with AD, but rel-
atively small therapeutic trials have generally failed to confirm efficacy.3 A number of com-
pounds that lack the 4-ring cyclopentanophenanthrene structure characteristic of steroid
hormones interact with estrogen receptors or exhibit estrogen-like properties. The selective
estrogen receptor modulators (SERMs) have estrogenic effects in some tissues but antiestrogenic
effects or no estrogenic effect in other tissues. Raloxifene, an oral SERM, is approved for
treatment of osteoporosis in postmenopausal women. In the Multiple Outcomes of Raloxifene
Evaluation trial, high-dose (120 mg/d) raloxifene reduced the risk of mild cognitive impairment
(relative risk 0.67, 95% confidence interval [CI] 0.46–0.98) and led to a nonsignificant reduc-
tion in AD risk (0.51, 95% CI 0.21–1.21).4 Studies of raloxifene effects on cognition in women
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without dementia provide inconsistent re-
sults,5–10 but some suggest benefit on a subset
of neuropsychological measures.
Raloxifene has not been evaluated as treat-
ment for AD. In consideration of large-scale
efficacy trials, we undertook a pilot trial in
postmenopausal women with late-onset AD
of mild to moderate severity to determine
whether raloxifene improves cognitive func-
tion and to provide an estimate of the treat-
ment effect.
METHODS Design and setting. This pilot study was con-
ducted as a randomized, double-blind, placebo-controlled trial,
with enrollment between September 2006 and December 2009
and a planned treatment period of 12 months. The primary
research question was whether raloxifene compared with
placebo improves cognitive function in women with AD.
Participants were assigned to oral raloxifene hydrochloride
given as two 60-mg tablets once daily or identical-appearing
placebo. The dose was based on findings in the Multiple
Outcomes of Raloxifene Evaluation trial, in which reductions
in risk of cognitive impairment were seen with the 120 mg/d
dose but not with the 60 mg/d dose.4 Interventions took place
on the campus of Indiana University School of Medicine and
Kaiser Permanente Medical Center (Santa Rosa, CA). To
facilitate recruitment, a third clinical site was established in
2008 on the campus of Southern Illinois University.
Coordination and data management occurred at Stanford
University. The study was monitored by an external data and
safety monitoring board.
Standard protocol approvals, registrations, and patient
consents. The study was approved by institutional review
boards of Indiana University, Kaiser Permanente Division of
Research, Southern Illinois University, and Stanford Uni-
versity. The protocol is registered at ClinicalTrials.gov
(NCT00368459). Participants provided written informed
consent, or assent with written consent of their next of kin or
legally authorized representative.
Participants. Participants were postmenopausal women with
dementia beginning at age 60 years or older, with probable
AD11 of mild to moderate severity, on a stable dose of a cholin-
esterase inhibitor. Women using raloxifene or menopausal hor-
mone therapy were ineligible, but we did not exclude women
using other drugs for osteoporosis treatment. Table e-1 on the
Neurology® Web site at Neurology.org provides details of
inclusion criteria.
Randomization. Trial eligibility was assessed at screening and
confirmed at the coordination center. To ensure approximately
equal allocation of women by dementia severity, assignment by
the study epidemiologist to raloxifene or placebo in a 1:1 ratio
used block randomization (concealed block size of 4) stratified
by clinical site and dementia severity (mild severity, screening
Mini-Mental State Examination12 scores 20 to 26; moderate
severity, scores 12 to 19). The trial epidemiologist prepared a
randomization list using a random number generator (Proc
Plan procedure, SAS version 9.2; SAS Institute, Cary, NC).
The investigational drug pharmacist prepared and labeled study
medications in bottles containing somewhat more than a
3-month supply (200 tablets). The randomization list included
a unique, randomly assigned product identification number.
Labeled bottles specifying “raloxifene 60 mg or placebo tablets”
were maintained at clinical sites. On determination of trial
eligibility and based on dementia severity stratum, the
epidemiologist informed the site coordinator which product
identification number was assigned to the participant.
Participants, caregivers, staff, and investigators other than the
epidemiologist and pharmacist were masked to group assignment.
Endpoints. In intent-to-treat analyses, the primary endpoint,
compared between treatment groups, was change in the
Alzheimer’s Disease Assessment Scale, cognitive subscale13
(ADAS-cog) assessed at baseline and 12 months. Planned
secondary endpoints were change in global dementia rating,
function, behavior, other cognitive test scores, caregiver burden,
and caregiver distress. Outcomes were assessed at baseline and 6
and 12 months, and the ADAS-cog was also assessed at 3 and 9
months. Pill counts at each visit were used to assess adherence.
Change in global dementia rating was assessed with the Clin-
ical Dementia Rating–Sum of Boxes score14 obtained by a certi-
fied clinician using information from the participant and a
knowledgeable informant. The standard Clinical Dementia Rat-
ing score was also recorded. Functional assessment used the Alz-
heimer’s Disease Cooperative Study Activities of Daily Living
Inventory.15 Ratings on this 23-item, informant-based instru-
ment are derived from basic and instrumental daily activities dur-
ing the preceding 4 weeks. Behavior was assessed with the
Neuropsychiatric Inventory16 during a structured interview with
the participant’s caregiver informant, with items from 10 behav-
ioral domains. Secondary cognitive outcomes13,17–25 emphasized
skills posited to be affected by a drug that interacts with estrogen
receptors (verbal episodic memory, working memory and execu-
tive functions, and semantic memory). A global cognitive com-
posite score was calculated as the weighted sum of component
standardized scores weighted by the inverse intertest correlation
matrix.26 Caregiver burden was assessed by the 22-item self-report
Zarit Caregiver Burden Interview,27 and caregiver distress was
rated with the 10-item Caregiver Distress Scale given as part of
the Neuropsychiatric Interview.16 At the study conclusion, in-
formants indicated on a 5-point Likert scale whether they
thought family members had received raloxifene or placebo.
Demographic and clinical variables. Demographic informa-
tion, medical history, and medication use were obtained by struc-
tured questionnaires. Body mass index (kg/m2) was calculated
from measured height and weight.
Statistical analysis. For this pilot trial, we did not anticipate
power to detect small, meaningful between-group differences
over a 12-month treatment period but specified that we would
report trends (a , 0.1) as a guide to future studies. Planned
recruitment of 72 participants was based on feasibility and
anticipated resources. An intent-to-treat analysis was performed
for all participants who completed baseline assessments, with
missing data imputed from group mean changes. Standardized
differences (effect sizes) were calculated from test means and SDs
from baseline test data for the entire sample.
Initial analyses explored possible differences in baseline charac-
teristics between treatment groups, analyzed by t test for contin-
uous variables or x2 for categorical variables. Between-group
change scores were analyzed by analysis of covariance with baseline
scores, age, and education as covariates. An exploratory analysis of
the ADAS-cog evaluated outcomes with repeated-measures general
linear models according to a 5 3 2 3 3 factorial design. The
within-subjects factor was time (baseline, 3, 6, 9, and 12 months)
and between-subjects factors were treatment (raloxifene, placebo)
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and clinical site. We used SAS Proc Mixed to model the covariance
structure and maintain cases with missing outcome data. We used
polynomial contrasts to investigate the nature of the treatment-by-
time interaction.
Classification of evidence. This interventional study provides
Class I evidence that 12-month treatment with raloxifene 120
mg/d does not have a significant cognitive effect in women
with late-onset AD of mild to moderate severity (mean
between-groups standardized difference on the ADAS-cog of
0.03, 95% CI 20.39 to 0.44, 2-tailed p 5 0.89). The study
lacked the precision to exclude a small effect.
RESULTS Forty-seven women were assessed in per-
son for eligibility, and 42 were randomly assigned
to a treatment group (21 raloxifene, 21 placebo).
Thirty-nine women provided baseline and 12-month
outcome data. Three other women who provided
baseline data were included in intent-to-treat analyses
(figure). Women ranged in age from 68 to 84 years
(table 1). Women in the raloxifene group were slightly
older and slightly less well educated than women in the
placebo group but were otherwise similar, and
subsequent analyses adjusted for age and education.
At baseline, ADAS-cog performance, dementia rating,
function, and behavioral symptoms did not differ
significantly, and treatment groups were otherwise
similar (table 1; baseline neuropsychological test
scores are given in table e-2). There was no effect of
site on study outcomes, and analyses were pooled
across sites.
Primary efficacy endpoint, ADAS-cog. At 12 months,
women in both treatment groups showed modest de-
clines in mean ADAS-cog performances (table 2).
The 12-month decline in the placebo group was
similar to that reported in other clinical trials
involving patients with mild to moderate
dementia.28 The baseline ADAS-cog SD was 11.4
points, and the 12-month between-groups mean
difference of 0.3 points represented a standardized
difference (standardized effect size) of only 0.03
(95% CI 20.39 to 0.44). Effects were similar in
subgroups defined by baseline severity (mild vs
moderate dementia; interaction p value 5 0.44,
2-tailed analysis of covariance).
Secondary endpoints. Dementia rating, function, and
behavior declined in both treatment groups, with-
out significant differences between groups (table 2).
At 12 months, the standardized difference on the
global cognitive composite score showed a medium
effect size (.0.5 SD) in favor of raloxifene that,
however, was not significant (p 5 0.38, 2-tailed
analysis of covariance) (table 2). For individual
neuropsychological tests, there were no consistent
between-group differences (table 2). We found a
large (.0.8 SD), nominally significant effect
favoring raloxifene for maze performance, and a
medium, nonsignificant effect on one verbal
memory task (word list delayed recall). We noted
small (.0.2 SD), nonsignificant effect sizes favoring
raloxifene on a related verbal memory task (word list
immediate recall), on 2 writing measures, and on 2
measures of semantic memory. We noted a small,
nonsignificant effect favoring placebo on a different
semantic memory task. Caregiver burden and
caregiver distress increased modestly over time in
both treatment groups (table 2).
Exploratory analyses: Efficacy outcomes before 12
months. Women in the raloxifene group showed small
improvements in the ADAS-cog at 3, 6, and 9 months;
women in the placebo group declined at each time
point (table 3). The standardized difference was
nominally significant at 3 months, corresponding to
a mean difference of 3.8 points on the ADAS-cog, but
not at other time points. At 6 months, functional
decline was greater in the raloxifene group. Declines
Figure Flowchart of study enrollment and follow-up
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in dementia rating and behavior—as well as changes
on individual neuropsychological scores—did not
differ significantly between treatment groups (table
4). Medium effect sizes (.0.5 SD) were noted on 2
tasks, one favoring raloxifene (a measure of semantic
memory) and one favoring placebo (an executive
functions task [Trail Making Test, part B]).
Other exploratory analyses. Mixed linear models pre-
dicted a nonsignificant difference in the annual rate
of change in the ADAS-cog of 0.4 points (95% CI
23.0 to 3.8) favoring the raloxifene group. The
effect of group is also very small if time is modeled
as a quadratic function. The ADAS-cog may be
relatively insensitive to cognitive change in patients
with mild disease,29 and the rate difference was more
apparent among women with moderate dementia
(n 5 17), where the mean annual change in the
placebo group was 27.6 (95% CI 23.0 to 12.2)
points per year and the predicted difference was 3.3
(22.7 to 9.4) points, favoring the raloxifene group.
For women with mild dementia (n 5 25), the mean
annual change in the placebo group was 20.4 (23.0
to 2.7) and the predicted between-groups difference
was21.6 (25.6 to 2.4; interaction p value5 0.079).
Adherence. Based on pill count, the proportion of
adherent women did not differ between treatment
groups. Of the 39 study completers, 17 of 18
women in the raloxifene group (one with missing
data) and 20 of 20 women in the placebo group took
at least 80% of allocated study drug. The one non-
adherent participant took 77% of her allotted study
drug.
Safety. Three participants experienced serious adverse
events, including one death. In the raloxifene
group, one woman developed pneumonia and con-
gestive heart failure, had an ischemic stroke, and
died; another was diagnosed with colon cancer. A
woman in the placebo group was hospitalized for
hallucinations and agitation (adverse event details
are in table e-3).
Adequacy of blinding. During the final visit, inform-
ants of 40 participants provided Likert scale responses
regarding suspected treatment arm. Responses did
not differ between treatment groups (p 5 0.75, 2-
tailed t test). Five informants from each group were
“very certain” or “somewhat certain” that their family
members had received raloxifene.
DISCUSSION Results from this randomized, double-
blind, placebo-controlled pilot trial confirm the
12-month feasibility of high-dose (120 mg/d)
raloxifene therapy in women with late-onset AD of
mild to moderate severity. Ninety percent of raloxifene
group participants contributed outcomes at 12 months,
and all but one took at least 80% of the allocated
treatment. Caregiver blinding was maintained.
However, recruitment was more difficult than
anticipated, and the study sample did not reflect the
racial and ethnic diversity of the general population.
One woman in the raloxifene group experienced a
possibly related, serious adverse event: ischemic stroke
followed by death. Raloxifene is linked to fatal stroke
in women at high risk defined by the Framingham
stroke score.30 In future trials, high stroke risk could be
considered exclusionary.
This pilot trial was not designed to identify small
effects of raloxifene in the range provided by
approved Alzheimer therapies such as donepezil or
memantine. We found that raloxifene did not have
a large or medium effect on the prespecified primary
outcome. Based on the 12-month change of
ADAS-cog performance compared between groups,
the mean effect size was negligible, averaging only
Table 1 Participant characteristics at baseline, by group
Characteristica
Raloxifene group
(n 5 21)
Placebo group
(n 5 21)
Dementia severity,b n (%)
Mild 13 (62) 12 (57)
Moderate 8 (38) 9 (43)
Age, y 77.7 (4.5) 74.1 (5.1)a
Education, y 13.2 (2.4) 14.0 (2.0)a
Race or ethnicity, n (%)
White, non-Hispanic 20 (95) 21 (100)
Black, non-Hispanic 1 (5) 0 (0)
Surgical menopause, n (%) 9 (43) 8 (38)
Body mass index, kg/m2 26.0 (5.0) 25.7 (4.7)
Systolic blood pressure, mm Hg 131 (17) 132 (24)
Diastolic blood pressure, mm Hg 66 (9) 68 (16)
ADAS-cog, error score13 (70–0) 24.3 (11.0) 25.8 (12.0)
Mini-Mental State Examination12 (0–30) 21.2 (4.9) 19.4 (6.2)
Clinical Dementia Rating14 (3–0) 1.0 (0.5) 1.2 (0.6)
Clinical Dementia Rating–Sum of Boxes
(18–0)
5.5 (3.0) 6.8 (3.1)
Activities of daily living15 (0–78) 63.5 (12.4) 58.3 (14.8)
Neuropsychiatric Inventory16 (120–0) 5.2 (6.6) 5.8 (7.8)
Caregiver burden interview score27
(110–22)
38.6 (11.9) 43.7 (11.8)
Caregiver distress16 (50–0) 4.0 (5.6) 2.8 (3.1)
Abbreviation: ADAS-cog 5 Alzheimer’s Disease Assessment Scale, cognitive subscale.
Data are shown as n (%) or mean (SD). For baseline values of outcome measures, numbers in
parentheses provide the range of possible scores. Higher values represent less impairment
on activities of daily living but more impairment for the ADAS-cog, Clinical Dementia Rating
and Clinical Dementia Rating–Sum of Boxes, the Neuropsychiatric Inventory, and caregiver
burden and distress.
a For between-group comparisons—using Wilcoxon rank sum test, t test, or x2 test, as
appropriate—all 2-tailed probabilities .0.1 except age (p 5 0.02) and education (p 5 0.1).
bSeverity was defined by Mini-Mental State Examination scores of 20–26 (mild) and 12–19
(moderate).
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three-tenths of a point, or 0.03 SD, on this test. Early
cognitive benefit of raloxifene compared with placebo
(0.33 SD at 3 months) was not sustained at later
time points. Secondary analyses of dementia rating,
activities of daily living, and behavior—as well as
caregiver burden and distress—also failed to suggest
meaningful benefit, although power to detect treat-
ment effects was limited.
In secondary analyses based on mean change at 12
months, the global cognition composite measure
showed a medium effect size (.0.5 SD) in favor of
raloxifene that, however, was not significant; this
Table 2 Twelve-month changes for primary and secondary outcomes
Outcome (range of potential scores)
Raloxifene group
(n 5 21)
Placebo group
(n 5 21)
Standardized differencea
(95% CI)
Primary outcome
ADAS-cog13 (70–0) 23.2 23.5 0.03 (20.39 to 0.44)
Noncognitive secondary outcomes
Clinical Dementia Rating14 (3–0) 20.5 20.3 20.30 (21.16 to 0.56)
Clinical Dementia Rating–Sum of Boxes (18–0) 22.6 22.0 20.18 (20.75 to 0.39)
Activities of daily living15 (0–78) 29.1 24.5 20.34 (20.84 to 0.18)
Neuropsychiatric Inventory16 (120–0) 22.3 22.5 0.02 (20.65 to 0.70)
Cognitive secondary outcomes
Word list learning,13,17 immediate recallb (0–30) 0.3 21.0 0.29 (20.20 to 0.77)
Word list learning, delayed recallb (0–10) 0.5 20.3 0.69 (20.04 to 1.42)c
East Boston Memory Test,18 immediate recall (0–12) 21.5 21.8 0.10 (20.59 to 0.79)
East Boston Memory Test, delayed recall (0–12) 20.1 20.2 0.04 (20.67 to 0.75)
Digit ordering,19 span (0–6) 20.3 20.4 0.02 (20.58 to 0.62)
Maze completion,17 s (240–0) 29.1 281.0 0.89 (0.03 to 1.75)d
Number cancellation,17 targets (0–40) 21.3 22.9 0.18 (20.28 to 0.64)
Trail Making Test,20 part A, s (300–0) 230.8 215.1 20.16 (20.64 to 0.31)
Trail Making Test, part B, s (300–0) 4.4 22.2 0.09 (20.64 to 0.81)
Category fluency,21 animals (‡0) 22.1 22.9 0.16 (20.35 to 0.66)
Boston Naming Test22 (0–30) 23.0 21.2 20.28 (20.77 to 0.20)
Narrative writing23 (0–11) 20.2 20.5 0.24 (20.24 to 0.72)
Narrative writing, semantic density24 (0–21) 20.2 21.3 0.36 (20.09 to 0.82)
Semantic retrieval,25 correct names (0–16) 21.1 21.9 0.24 (0.43 to 0.90)
Semantic retrieval, recognition (0–32) 20.7 22.0 0.32 (20.34 to 0.98)
Visuoconstructive performancee (0–15) 20.6 21.0 0.11 (20.29 to 0.50)
Mini-Mental State Examination12 (0–30) 22.5 21.6 20.17 (20.65 to 0.31)
Cognitive composite score, standardized unitsf 20.6 21.1 0.52 (20.62 to 1.66)
Caregiver secondary outcomes
Caregiver burden interview score27 (110–22) 23.1 22.0 20.12 (20.67 to 0.44)
Caregiver distress16 (50–0) 21.5 21.0 20.07 (20.72 to 0.57)
Abbreviations: ADAS-cog 5 Alzheimer’s Disease Assessment Scale, cognitive subscale; CI 5 confidence interval.
Group differences in mean test scores are adjusted for baseline score, age, and education. In all instances, a positive
change indicates improved performance. Signs were changed for ADAS-cog, Clinical Dementia Rating, and Clinical
Dementia Rating–Sum of Boxes, Neuropsychiatric Inventory, caregiver burden, and caregiver distress.
aStandardized difference (effect size), calculated as the mean between-group difference (raloxifene minus placebo)
divided by the SD of the test; SDs for standardization used baseline test data for the entire sample.
b From the 10-item ADAS-cog17 word list, with 3 immediate recall trials and one delayed recall trial.
cp 5 0.06, 2-tailed analysis of covariance.
dp 5 0.04, 2-tailed analysis of covariance.
eExtended scoring of ADAS-cog drawings6 (circle, 2 points; diamond, 3 points; overlapping rectangles, 4 points; cube,
6 points).
f Calculated as the weighted average of standardized test scores for the ADAS-cog and cognitive secondary outcomes
weighted by the inverse interest correlation matrix.26
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Table 3 Exploratory outcome: Change in ADAS-cog score between baseline and 3, 6, 9, and 12 months
Time point,
mo
Mean change,
raloxifene group
Mean change, placebo
group
Between-group
difference
Standardized difference
(95% CI)
Nominal
p valuea
3 1.5 22.3 3.8 0.33 (0.003 to 0.66) 0.048
6 0.7 21.8 2.5 0.22 (20.10 to 0.54) 0.18
9 1.1 21.3 2.4 0.21 (21.10 to 0.52) 0.17
12 23.2 23.5 0.3 0.03 (20.39 to 0.44) 0.89
Abbreviations: ADAS-cog 5 Alzheimer’s Disease Assessment Scale, cognitive subscale; CI 5 confidence interval.
Values represent mean change at each time point, adjusted for baseline score, age, and education. A positive mean change
represents improved performance, compared with baseline. A positive between-group difference represents better
performance by the raloxifene group.
a Two-tailed analysis of covariance, unadjusted for multiple comparisons.
Table 4 Exploratory outcomes: Six-month changes for cognitive and noncognitive outcomes
Outcome
Raloxifene group
(n 5 21)
Placebo group
(n 5 21)
Standardized difference
(95% CI)
ADAS-cog 0.7 21.8 0.22 (20.10 to 0.54)
Noncognitive outcomes
Clinical Dementia Rating 20.2 20.2 20.08 (20.74 to 0.57)
Clinical Dementia Rating–Sum of Boxes 20.8 21.0 0.07 (20.44 to 0.58)
Activities of daily living 26.9 20.3 20.48 (20.82 to 20.15)a
Neuropsychiatric Inventory 20.7 23.1 0.35 (20.35 to 1.04)
Caregiver outcomes
Caregiver burden interview score 22.0 21.0 20.08 (20.65 to 0.49)
Caregiver distress 20.2 20.60 0.10 (20.46 to 0.67)
Other cognitive outcomes
Word list learning, immediate recall 0.2 0.1 0.03 (20.27 to 0.33)
Word list learning, delayed recall 20.04 20.2 0.15 (20.27 to 0.58)
East Boston Memory Test, immediate recall 20.4 20.5 0.02 (20.59 to 0.63)
East Boston Memory Test, delayed recall 0.4 20.5 0.40 (20.23 to 1.02)
Digit ordering, span 20.1 20.05 20.07 (20.51 to 0.36)
Maze completion, s 224.0 215.9 20.10 (20.69 to 0.49)
Number cancellation, no. of targets 20.1 21.4 0.14 (20.35 to 0.63)
Trail Making Test, part A, s 216.3 27.6 20.09 (20.51 to 0.33)
Trail Making Test, part B, s 228.9 10.1 20.51 (21.11 to 0.08)
Category fluency, animals 21.6 21.4 20.05 (20.42 to 0.32)
Boston Naming Test 21.7 20.4 20.22 (20.56 to 0.13)
Narrative writing 0.01 20.01 0.02 (20.46 to 0.50)
Narrative writing, semantic density 0.3 20.2 0.15 (20.29 to 0.60)
Semantic retrieval, correct names 0.03 21.6 0.44 (20.08 to 0.95)
Semantic retrieval, recognition 20.7 22.8 0.54 (20.32 to 1.40)
Visuoconstructive performance 20.6 21.0 0.11 (20.29 to 0.50)
Mini-Mental State Examination 20.8 20.6 20.05 (20.44 to 0.35)
Cognitive composite score, standardized units 20.5 20.6 0.16 (20.74 to 1.07)
Abbreviations: ADAS-cog 5 Alzheimer’s Disease Assessment Scale, cognitive subscale; CI 5 confidence interval.
Group differences in mean test scores are adjusted for baseline score, age, and education. In all instances, a positive
change indicates improved performance. Signs were changed for ADAS-cog, Clinical Dementia Rating and Clinical
Dementia Rating–Sum of Boxes, Neuropsychiatric Inventory, caregiver burden, and caregiver distress.
ap 5 0.006, 2-tailed analysis of covariance.
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difference was smaller at 6 months. Nonsignificant
differences favoring raloxifene on some verbal mem-
ory tasks could have been observed on the basis of
chance. However, raloxifene is sometimes reported to
benefit verbal memory in older postmenopausal
women without dementia,5,8 and future studies might
examine raloxifene effects within this cognitive
domain more closely.
These results provide information to guide consid-
eration and design of future trials. The essentially null
effect of raloxifene on the primary outcome implies a
low likelihood of positive results but does not exclude
the possibility of modest cognitive benefit or harm.
The upper tail of the 95% CI represents a small
(0.2 # SD , 0.5) effect but corresponds to about
5 points on the ADAS-cog, a difference that—despite
weak evidence for validity31—falls within a com-
monly accepted range of clinical relevance. The
ADAS-cog is a common endpoint in Alzheimer treat-
ment trials, but it is possible that other neuropsycho-
logical outcomes could be more sensitive to any
cognitive effect of raloxifene.
We conclude that 12 months’ treatment with ral-
oxifene 120 mg/d compared with placebo has no
more than a small effect on the ADAS-cog in women
with late-onset AD of mild to moderate severity. This
conclusion may not pertain to short-term (e.g.,
3-month) effects of raloxifene, where we found a
nominally significant difference between groups on
the ADAS-cog; to effects that might require more
than 12 months to emerge; or to selective effects
within specific cognitive domains. Finally, results do
not generalize to populations or outcomes not studied
in this trial, including raloxifene effects on cognitive
outcomes in women without dementia, raloxifene
effects on AD risk, or effects of other SERMs on
cognitive outcomes.
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